S-1, Oxaliplatin, Cadonilimab

Phase 2Monoclonal antibody

S-1, Oxaliplatin, Cadonilimab is one of 48 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Camptosar

EEastern Cooperative Oncology Group

Phase 3

5 2

Gemzar

Johnson & Johnson

Preclinical

—3

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 4

S-1, Oxaliplatin, Cadonilimab

SSichuan University

Phase 2

1 5

S1,

CChinese Academy of Medical Sciences

Preclinical

17 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 7

Glutamine

Sanofi

Preclinical

1 8

Induction Phase1

Genmab

Preclinical

1 9

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

1 10

Cox-2 Inhibitor

SSeoul National University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Gastric Cancer

NCT06213519

Clinical

Trials by Indication[1]

Gastroesophageal Junction Adenocarcinoma1 trial

To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Unknown status·SSichuan University·Phase 2·NCT05948449·37 enrolled

Gastric Cancer1 trial

HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis

Not yet recruiting·SSichuan University·Phase 2·NCT06213519·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for S-1, Oxaliplatin, Cadonilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S-1, Oxaliplatin, Cadonilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S-1, Oxaliplatin, Cadonilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: SSichuan University

S-1, Oxaliplatin, Cadonilimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Gastroesophageal Junction Adenocarcinoma1 trial

Gastric Cancer1 trial

References

Drug Info

Quick Facts

Related News